Primary progressive versus relapsing-onset multiple sclerosis: Presence and prognostic value of cerebrospinal fluid oligoclonal IgM

Multiple Sclerosis Journal

Volumn 17, Issue 3, 2011, Pages 303-311

  Sola, Patrizia ^a   Mandrioli, Jessica ^a   Simone, Anna M ^a   Ferraro, Diana ^a   Bedin, Roberta ^a   Annecca, Rosanna ^a   Venneri, Maria G ^a   Nichelli, Paolo F ^a   Merelli, Elisa ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

cerebrospinal fluid oligoclonal IgM; primary progressive multiple sclerosis; prognosis

Indexed keywords

BIOLOGICAL FACTOR; IMMUNOGLOBULIN M; OLIGOCLONAL BAND;

ADULT; ARTICLE; CALCULATION; CEREBROSPINAL FLUID; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; ONSET AGE; PATHOGENESIS; PROGNOSIS; RELAPSE;

EID: 79953216040     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510386996     Document Type: Article

References (41)

1. Lublin FD and Reingold SC Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996 ; 46: 907-911. (Pubitemid 26134623)
2. Thompson AJ, Montalban X., Barkhof F., Brochet B., Filippi M., Miller DH, et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 2000 ; 47: 831-835. (Pubitemid 30390209)
3. Miller DH and Leary SM Primary-progressive multiple sclerosis. Lancet Neurol 2007 ; 6: 903-912. (Pubitemid 47405002)
4. Compston A. and Coles A. Multiple sclerosis. Lancet 2008 ; 372: 1502-1517.
5. Bradl M. and Lassmann H. Progressive multiple sclerosis. Semin Immunopathol 2009 ; 31: 455-465.
6. Revesz T., Kidd D., Thompson AJ, Barnard RO and McDonald WI A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 1994 ; 117: 759-765. (Pubitemid 24281838)
7. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M. and Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000 ; 47: 707-717. (Pubitemid 30390191)
8. Kutzelnigg A., Lucchinetti CF, Stadelmann C., Brück W., Rauschka H., Bergmann M., et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005 ; 128: 2705-2712. (Pubitemid 41552953)
9. Lassmann H., Bruck W. and Lucchinetti CF The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007 ; 17: 210-218. (Pubitemid 46466140)
10. Noseworthy JH In: Filippi M, Comi G (eds) Topics in neuroscience: primary progressive multiple sclerosis. Milano: Springer-Verlag Italia, 2002, pp. iv - v.
11. Giovannoni G., Lai M., Thorpe J., Kidd D., Chamoun V., Thompson AJ, et al. Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging. Neurology 1997 ; 48: 1557-1565.
12. Hohlfeld R. Immunological factors in primary progressive multiple sclerosis. Mult Scler 2004 ; 10 (suppl 1): S16 - S21.
13. Montalban X. Primary progressive multiple sclerosis. Curr Op Neurol 2005 ; 18: 261-266. (Pubitemid 40813752)
14. McDonnell GV and Hawkins SA Clinical study of primary progressive multiple sclerosis in Northern Ireland, UK. J Neurol Neurosurg Psychiatry 1998 ; 64: 451-454. (Pubitemid 28195944)
15. Sumelahti M-L., Tienari PJ, Hakama M. and Wikström J. Multiple sclerosis in Finland: incidence trends and differences in relapsing remitting and primary progressive disease courses. J Neurol Neurosurg Psychiat 2003 ; 74: 25-28. (Pubitemid 36069031)
16. Villar LM, Masterman T., Casanova B., Gómez-Rial J., Espiño M., Sádaba MC, et al. CSF oligoclonal band patterns reveal disease heterogeneity in multiple sclerosis. J Neuroimmunol 2009 ; 211: 101-104.
17. Mandrioli J., Sola P., Bedin R., Gambini M. and Merelli E. A multifactorial prognostic index in multiple sclerosis: cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease. J Neurol 2008 ; 255: 1023-1031.
18. Villar LM, Gonzales-Porquè P., Masjuan J., Alvarez-Cormeno JC, Bootello A. and Keir G. A sensitive and reproducible method for the detection of oligoclonal IgM bands. J Immunol Methods 2001 ; 258: 151-155. (Pubitemid 33016535)
19. Villar LM, Masjuan J., González-Porqué P., Plaza J., Sádaba MC, Roldán E., et al. Intrathecal IgM synthesis in neurological diseases. Relationship with disability in multiple sclerosis. Neurology 2002 ; 58: 824-826. (Pubitemid 34211568)
20. Villar LM, Masjuan J., González-Porqué P., Plaza J., Sádaba MC, Roldán E., et al. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in multiple sclerosis. Neurology 2002 ; 59: 555-559. (Pubitemid 34919989)
21. Villar LM, Masjuan J., González-Porqué P., Plaza J., Sádaba MC, Roldán E., et al. Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann Neurol 2003 ; 53: 222-226. (Pubitemid 36164004)
22. Villar JM, Sádaba MC, Roldán E., Masjuan J., González-Porqué P., Villarrubia N., et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in multiple sclerosis. J Clin Invest 2005 ; 115: 187-194. (Pubitemid 40385520)
23. Villar L., García-Barragán N., Espiño M., Roldán E., Sádaba M., Gómez-Rial J., et al. Influence of oligoclonal IgM specificity in multiple sclerosis disease course. Mult Scler 2008 ; 14: 183-187. (Pubitemid 351639626)
24. McDonald WI, Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001 ; 50: 121-127.
25. Polman CH, Reingold SC, Edan G., Filippi M., Hartung HP, Kappos L., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005 ; 58: 840-846. (Pubitemid 41746873)
26. Tremlett H., Paty D. and Devonshire V. The natural history of primary progressive MS in British Columbia, Canada. Neurology 2005 ; 65: 1919-1923. (Pubitemid 43970111)
27. Confavreux C. and Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006 ; 129: 606-616. (Pubitemid 43278223)
28. Khaleeli Z., Ciccarelli O., Manfredonia F., et al. Predicting progression in primary progressive multiple sclerosis: a 10-year multicenter study. Ann Neurol 2008 ; 63: 790-793. (Pubitemid 351945538)
29. Tremlett H., Zhao Y., Devonshire V and the UCB Neurologists. Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities. J Neurol 2009 ; 256: 374-381.
30. Koch M., Kingwell E., Rieckmann P. and Tremlett H. The natural history of primary progressive multiple sclerosis. Neurology 2009 ; 73: 1996-2002.
31. Meinl E., Krumbholz M. and Hohlfeld R. B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann Neurol 2006 ; 59: 880-892. (Pubitemid 43830920)
32. Mead RJ, Singhrao SK, Neal JW, Lassmann H. and Morgan BP The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J Immunol 2002 ; 168: 458-465. (Pubitemid 34014149)
33. Rosenbluth J., Schiff R., Liang WL and Dou W. Antibody-mediated CNS demyelination II. Focal spinal cord lesions induced by implantation of an IgM antisulfatide-secreting hybridoma. J Neurocytol 2003 ; 32: 265-276. (Pubitemid 38197826)
34. Villar L., Masterman T., Casanova B., Gómez-Rial J., Espiño M., Sádaba M., et al. CSF oligoclonal band patterns reveal disease heterogeneity in multiple sclerosis. J Neuroimmunol 2009 ; 211: 101-104.
35. Calabrese M., Rocca MA, Atzori M., Mattisi I., Bernardi V., Favaretto A., et al. Cortical lesions in primary progressive multiple sclerosis: a 2-year longitudinal MR study. Neurology 2009 ; 14: 1330-1336.
36. Pender MP The pathogenesis of primary progressive multiple sclerosis: antibody-mediated attack and no repair? J Clin Neurosci 2004 ; 11: 689-692. (Pubitemid 39164978)
37. Lucchinetti CF and Bruck W. The pathology of primary progressive multiple sclerosis. Mult Scler 2004 ; 10: S23 - S30.
38. Hochmeister S., Grundtner R., Bauer J., Engelhardt B., Lyck R., Gordon G., et al. Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis. J Neuropathol Exp Neurol 2006 ; 65: 855-865. (Pubitemid 44371231)
39. Bar-Or A. The immunology of multiple sclerosis. Semin Neurol 2008 ; 28: 29-45. (Pubitemid 351273082)
40. Serafini B., Rosicarelli B., Magliozzi R., Stille W. and Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004 ; 14: 164-174. (Pubitemid 38656388)
41. Aloisi F. and Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 2006 ; 6: 205-217. (Pubitemid 43290990)